To view the PDF file, sign up for a MySharenet subscription.

APN - Aspen - Further announcement regarding the acquisition of the

Release Date: 14/01/2011 09:02
Code(s): APN
Wrap Text

APN - Aspen - Further announcement regarding the acquisition of the pharmaceutical business of Sigma Pharmaceticals Limited ("SIGMA") by Aspen - conditions precedent met ASPEN PHARMACARE HOLDINGS LIMITED (Incorporated in the Republic of South Africa) (Registration number 1985/002935/06) Share code: APN ISIN: ZAE000066692 ("Aspen") FURTHER ANNOUNCEMENT REGARDING THE ACQUISITION OF THE PHARMACEUTICAL BUSINESS OF SIGMA PHARMACETICALS LIMITED ("SIGMA") BY ASPEN - CONDITIONS PRECEDENT MET Aspen shareholders are referred to the announcements released on the Securities Exchange News Service of the JSE Limited on 16 August 2010 and 23 November 2010, respectively, wherein, Aspen announced that the Aspen Group had reached formal agreement with Sigma to acquire the pharmaceutical business of Sigma on a debt- free basis for a cash consideration of A$900 million (approximately ZAR 6 148 million at current exchange rates) ("the Transaction"), and that the Transaction was subject to a number of conditions precedent. Aspen is pleased to announce that, following approval of the transaction received at the extraordinary General Meeting of Sigma`s Shareholders, held on 14 January 2011, all the conditions precedent to the Transaction have now been met and the Transaction is now unconditional. The Transaction is scheduled to complete on 31 January 2011. Woodmead 14 January 2011 Investment Bank and Mandated Lead Arranger and Sponsor to Aspen Debt Advisor Investec Bank Limited The Standard Bank of South (Registration number Africa Limited 1969/004763/06) and (Registration number Investec Bank (Australia) 1962/000738/06) Limited Date: 14/01/2011 09:02:02 Supplied by www.sharenet.co.za Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited (`JSE`). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.

Share This Story